Radar · Life Sciences in San Francisco
Best Life Sciences Companies in San Francisco, United States
The 892 best Life Sciences companies in San Francisco, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Xaira.
By Riya SenguptaFinancials
892companies tracked
$36.8Bdisclosed funding
9unicorns
582have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × SAN FRANCISCO
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
607kcombined LinkedIn audience
52%of audience held by top 3
9companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in San Francisco
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Lyell Immunopharma Developer of CAR- T therapy for cancer treatment 45Patents top 14%Innovation top 21%Funding top 24%Talent top 28% All 11 signals ▾Patentstop 14% Innovationtop 21% Fundingtop 24% Talenttop 28% Techtop 30% Moatbottom 46% Globalbottom 42% Marketbottom 32% Growthbottom 32% Newsbottom 23% Fin. healthbottom 18% Patents: 163 patents matched (strict assignee match) · 154 filings since 2022 vs 9 in 2017-21 Innovation: 163 patents (top 13% of patent-holders) · 154 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $493M | 10 mo ago | Public | 224 224 → 233 (+4%) · sector median +24% | Stan Riddell Co-Founder | WordPressMySQLPHP+16 | 163 patents Patents concentrated in chemistry & materials | — |
| 2 | Quince Therapeutics Developer of therapeutics for orthopedic diseases 53Funding top 13%Growth top 37%Tech top 44%Moat top 48% All 8 signals ▾Fundingtop 13% Growthtop 37% Techtop 44% Moattop 48% Talentbottom 49% Marketbottom 37% Newsbottom 37% Globalbottom 37% Funding: Raised $420M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $420M | 1 mo ago | Public | 21 | Dirk Thye CEO | DrupalPHPZURB Foundation+20 | — | — |
| 3 | Innovaccer 🦄 Developer of healthcare data platforms and artificial intelligence agent software 93Funding top 23%Tech top 25%AI top 25%Moat top 25% All 13 signals ▾Fundingtop 23% Techtop 25% AItop 25% Moattop 25% Markettop 26% Fin. healthtop 28% Talenttop 28% Innovationtop 29% Patentstop 32% Growthtop 33% Producttop 38% Globaltop 42% Newsbottom 24% Funding: Raised $379M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) Tech: 43 technologies across 6/8 capability areas · Cloud: Amazon S3, Amazon Ses rank vs industry peers · Fliar Intelligence Index 93/100 | $379M | 17 mo ago | Series F | 1,003 1,003 → 1,712 (+71%) · sector median +24% | Abhinav Shashank Co-Founder & CEO | WebflowGSAPNginx+22 | 30 patents Integrating and analyzing de‑identified healthcare data across clouds for clinical decision support | 1 partnership |
| 4 | Cellares Manufacturer of a medical device for cell-based therapy 82Funding top 15%News top 19%Innovation top 23%Growth top 25% All 11 signals ▾Fundingtop 15% Newstop 19% Innovationtop 23% Growthtop 25% Patentstop 27% Moattop 28% Partnerstop 31% Talenttop 35% Markettop 41% Techtop 43% Globalbottom 39% Funding: Raised $355M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 9 BI events in 12 mo (of 25 tracked, 4 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 82/100 | $355M | 4 mo ago | Series D | 154 | Fabian Gerlinghaus Co-Founder & CEO | WordPressApple iCloud MailGoogle Workspace+32 | 89 patents Patents concentrated in transport & manufacturing processes | 1 partnership · 1 expansion · 1 award |
| 5 | Neurona Therapeutics Developer of cell-based therapies to treat intractable neurological diseases 55Funding top 22%Moat top 31%Growth top 32%AI top 45% All 8 signals ▾Fundingtop 22% Moattop 31% Growthtop 32% AItop 45% Talentbottom 49% Marketbottom 43% Globalbottom 39% Techbottom 30% Funding: Raised $316M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $316M | 14 mo ago | Acquired | 67 67 → 116 (+73%) · sector median +24% | Cory Nicholas CEO | Apple iCloud MailApache HTTP ServerMicrosoft Advertising+5 | — | 1 award |
| 6 | Terremoto Developer of small-molecule therapeutics for cancer treatment 60Funding top 15%Talent top 28%Moat top 31%Growth top 35% All 7 signals ▾Fundingtop 15% Talenttop 28% Moattop 31% Growthtop 35% Techtop 49% Marketbottom 41% Globalbottom 36% Funding: Raised $250M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 60/100 | $250M | 2 mo ago | Series C | 35 | Matt Jacobson Co-Founder | WordPressBugHerdZendesk+24 | — | — |
| 7 | Merge Labs Developer of brain-computer interfaces to maximize human ability, agency, experience 48Talent top 28%Funding top 31%AI top 45%Patents top 49% All 8 signals ▾Talenttop 28% Fundingtop 31% AItop 45% Patentstop 49% Innovationbottom 49% Techbottom 45% Globalbottom 42% Marketbottom 31% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $250M | 5 mo ago | Seed | — | Sumner Norman Co-Founder | Apple iCloud MailGoogle WorkspaceNode.js+9 | 40 patents Real-time multi-user AR collaboration and interactive media streaming platforms | — |
| 8 | Tenaya Therapeutics Developer of regenerative and gene therapeutics for heart failure | $248M | 16 mo ago | Public | 141 141 → 93 (-34%) · sector median +24% | Benoit Bruneau Co-Founder | WordPressDrupalMySQL+24 | 207 patents Engineered AAV capsids and CRISPR guides for cardiac gene‑therapy targeting PLN mutations | — |
| 9 | Chai Discovery 🦄 Developer of artificial intelligence models for de novo molecular design 72Funding top 14%Talent top 28%AI top 30%Moat top 32% All 7 signals ▾Fundingtop 14% Talenttop 28% AItop 30% Moattop 32% Markettop 48% Globalbottom 48% Techbottom 42% Funding: Raised $230M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $230M | 6 mo ago | Series B | — | Joshua Meier Co-Founder | Framer SitesReactPriority Hints+7 | — | 1 partnership |
| 10 | Aligos Therapeutics Developer of therapies to treat hepatologic diseases and viral infections 50Patents top 12%Innovation top 16%Funding top 26%Moat top 35% All 12 signals ▾Patentstop 12% Innovationtop 16% Fundingtop 26% Moattop 35% Partnerstop 40% Techtop 42% Talenttop 45% Globaltop 46% Newstop 47% Marketbottom 46% Growthbottom 32% Fin. healthbottom 25% Patents: 503 patents matched (strict assignee match) · 389 filings since 2022 vs 114 in 2017-21 Innovation: 503 patents (top 5% of patent-holders) · 389 filings since 2022 vs 114 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $225M | 16 mo ago | Public | 70 70 → 99 (+41%) · sector median +24% | Lawrence Blatt CEO | DrupalApple iCloud MailPHP+21 | 503 patents RNA interference therapeutics and PD‑L1 immuno‑oncology using heterocyclic siRNA delivery compounds | — |
| 11 | Neuron23 AI-based drug discovery model for researchers 80Growth top 13%Funding top 18%Patents top 21%Moat top 21% All 10 signals ▾Growthtop 13% Fundingtop 18% Patentstop 21% Moattop 21% Innovationtop 23% AItop 45% Talentbottom 49% Globalbottom 40% Marketbottom 38% Newsbottom 18% Growth: Headcount 12 → 29 (+142%) across vintages · Fresh capital in last 24 mo Funding: Raised $214M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $214M | 11 mo ago | Series D | 29 29 → 28 (-3%) · sector median +24% | Adam Knight Founder & CBO | — | 49 patents LRRK2 kinase inhibitor therapeutics and biomarkers for Parkinson's disease treatment | 1 partnership |
| 12 | Braveheart Developer of a treatment for hypertrophic cardiomyopathy and related conditions | $185M | 7 mo ago | Series A | — | Travis Murdoch CEO & President | — | — | — |
| 13 | ORIC Pharmaceuticals Developer of small-molecule drugs for the treatment of cancers | $173M | 12 mo ago | Public | 86 86 → 135 (+57%) · sector median +24% | — | WordPressApple iCloud MailMicrosoft 365+20 | 229 patents Small-molecule oncology drugs targeting epigenetic regulators, EGFR mutants, CD73, and AKT pathways. | — |
| 14 | Senti Bio Developer of cell and gene therapies for patients living with incurable diseases 45Product top 14%Funding top 21%Talent top 22%Tech top 32% All 11 signals ▾Producttop 14% Fundingtop 21% Talenttop 22% Techtop 32% Innovationtop 34% Newsbottom 43% Moatbottom 43% Growthbottom 39% Globalbottom 39% Marketbottom 32% Fin. healthbottom 20% Product: 4 distinct product lines · Company stage: Public Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $158M | 1 mo ago | Public | 122 | Jim Collins Co-Founder | DrupalPHPSalesforce+24 | — | — |
| 15 | Atlas Data Provider of cloud-based data storage solutions utilizing DNA as a highly durable, low-cost, and permanent… 29Funding top 26%Moat top 40%Talent bottom 49%Tech bottom 45% All 6 signals ▾Fundingtop 26% Moattop 40% Talentbottom 49% Techbottom 45% Marketbottom 35% Globalbottom 33% Funding: Raised $155M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Soonicorn · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 29/100 | $155M | 13 mo ago | Seed | — | Varun Mehta CEO | WordPress Block EditorWordPressMySQL+19 | — | — |
| 16 | Alto Neuroscience AI-driven drug discovery platform for neurological diseases based on patients biomarkers 72Funding top 12%Patents top 25%Growth top 30%Moat top 32% All 11 signals ▾Fundingtop 12% Patentstop 25% Growthtop 30% Moattop 32% Innovationtop 33% Techtop 45% AItop 45% Globalbottom 49% Talentbottom 49% Newsbottom 44% Marketbottom 40% Funding: Raised $145M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Patents: 57 patents matched (strict assignee match) · 57 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $145M | 3 mo ago | Public | 34 | Amit Etkin Founder & CEO | BugHerdApple iCloud MailGoogle Workspace+15 | 57 patents Neuropsychiatric therapeutics: combinatorial dopaminergic/serotonergic drugs and EEG‑guided patient selection | 1 award |
| 17 | Mission Bio Provider of single cell multiomics platform for genotypic and phenotypic analysis 82Funding top 18%Tech top 21%Innovation top 25%Product top 25% All 10 signals ▾Fundingtop 18% Techtop 21% Innovationtop 25% Producttop 25% Talenttop 28% Moattop 31% Growthtop 37% Markettop 44% Globalbottom 39% Newsbottom 27% Funding: Raised $120M across 11 rounds · 11 rounds over 11 yrs (1.0/yr) Tech: 55 technologies across 6/8 capability areas · Cloud: Cloudflare, Vercel rank vs industry peers · Fliar Intelligence Index 82/100 | $120M | 10 mo ago | Series C | 109 109 → 89 (-18%) · sector median +24% | Adam Sciambi Co-Founder & Chief Technology Officer | SanityTurbopackSentry+34 | — | 1 launch · 1 partnership |
| 18 | Adela Developer of a platform for detection of cancer 57Funding top 22%Moat top 31%Patents top 38%Talent top 38% All 8 signals ▾Fundingtop 22% Moattop 31% Patentstop 38% Talenttop 38% Markettop 46% Innovationtop 49% Globalbottom 40% Newsbottom 22% Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $109M | 2 mo ago | Series A | 62 | Manish Agarwal Co-Founder | — | 15 patents Liquid biopsy nucleic acid extraction and sequencing library preparation technologies | 1 job opening · 1 partnership |
| 19 | Culture Biosciences Provider of biomanufacturing hardware and software tools for research purposes 67Funding top 20%Product top 25%Growth top 26%Moat top 31% All 10 signals ▾Fundingtop 20% Producttop 25% Growthtop 26% Moattop 31% Innovationtop 34% Talenttop 34% Techtop 45% Newsbottom 42% Marketbottom 41% Globalbottom 37% Funding: Raised $107M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Product: 6 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 67/100 | $107M | 6 mo ago | Series C | 35 35 → 67 (+91%) · sector median +24% | Chris Williams CEO | WebflowSwipercore-js+20 | — | — |
| 20 | Addition Therapeutics Developer of RNA-mediated genetic medicines 42Funding top 22%Talent top 38%Moat top 42%Market bottom 40% All 5 signals ▾Fundingtop 22% Talenttop 38% Moattop 42% Marketbottom 40% Globalbottom 36% Funding: Raised $106M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $106M | 6 mo ago | Series A | — | Kathleen Collins Founder | — | — | — |
| 21 | Nudge Developer of whole-brain interfaces intended to improve human-brain interaction | $100M | 10 mo ago | Series A | — | Quintin Frerichs Co-Founder | Apple iCloud MailGoogle WorkspaceRadix UI+8 | 12 patents Automated, low-interaction glucose monitoring and insulin delivery systems for diabetes care | — |
| 22 | STAR Therapeutics Developer of antibody therapies for multiple diseases 40Funding top 21%Moat top 42%Talent bottom 49%News bottom 45% All 6 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Newsbottom 45% Marketbottom 42% Globalbottom 38% Funding: Raised $90.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $90M | 8 mo ago | Series D | 43 | Adam Rosenthal Founder & CEO | — | — | — |
| 23 | Mirvie Provider of non-invasive diagnostic tests for pregnant women 69Growth top 20%Funding top 21%Patents top 24%Talent top 28% All 9 signals ▾Growthtop 20% Fundingtop 21% Patentstop 24% Talenttop 28% Innovationtop 32% Moattop 36% Techtop 46% Globalbottom 40% Marketbottom 35% Growth: Headcount 23 → 35 (+52%) across vintages · Fresh capital in last 24 mo Funding: Raised $90.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $90M | 11 mo ago | Series B | 35 35 → 41 (+17%) · sector median +24% | Mads Melbye Co-Founder | WebflowReactTypekit+21 | 49 patents Non‑invasive prenatal diagnostics via methylation and RNA biomarkers for pregnancy monitoring | — |
| 24 | TEMPEST THERAPEUTICS Developing targeted, immune-mediated oral cancer therapies for broad patient benefit 21Funding top 28%News top 36%Growth top 42%Tech top 49% All 9 signals ▾Fundingtop 28% Newstop 36% Growthtop 42% Techtop 49% Moatbottom 43% Talentbottom 41% Globalbottom 39% Marketbottom 23% Fin. healthbottom 13% Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY rank vs industry peers · Fliar Intelligence Index 21/100 | $88M | 2 mo ago | Public | 19 | Stephen B Chief Executive Officer | DrupalPHPparticles.js+25 | — | — |
| 25 | Aeovian Pharmaceuticals Developer of therpeutics for treating rare diseases | $87M | 6 mo ago | Series B | 10 10 → 13 (+30%) · sector median +24% | Stelios Tzannis Founder & COO | WixSentryBootstrap+12 | — | — |
| 26 | TRexBio Developer of therapeutics for immunology and cancer 45Funding top 20%Moat top 31%News top 46%Talent bottom 49% All 6 signals ▾Fundingtop 20% Moattop 31% Newstop 46% Talentbottom 49% Marketbottom 47% Globalbottom 36% Funding: Raised $85.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 45/100 | $85M | 4 mo ago | Series B | 65 | Johnston Erwin CEO | — | — | — |
| 27 | Electra Therapeutics Developer of therapies for immunological diseases and cancer | $84M | 8 mo ago | Series C | 4 | Adam Rosenthal Co-Founder & CEO | — | — | 1 launch |
| 28 | Mendra Developer of AI-enabled therapeutics for rare diseases with high unmet need | $82M | 4 mo ago | Series A | — | Joshua Grass Co-Founder & CEO | WebflowGSAPTypekit+12 | — | — |
| 29 | Faeth Therapeutics Provider of personalized nutritional programs against cancer | $67M | 10 mo ago | Acquired | 9 | Anand Parikh Founder & CEO | WebflowjsDelivrGoogle Hosted Libraries+9 | — | — |
| 30 | Ionetix Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy | $61M | 3 mo ago | Series C | 50 | Kevin Cameron CEO | WordPressMySQLPHP+24 | 9 patents Compact superconducting cyclotron systems for medical and research particle acceleration | 3 job openings |
| 31 | NewLimit 🦄 Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension 62Funding top 22%Talent top 28%Growth top 35%AI top 45% All 9 signals ▾Fundingtop 22% Talenttop 28% Growthtop 35% AItop 45% Techtop 46% Moattop 47% Marketbottom 36% Globalbottom 36% Newsbottom 18% Funding: Raised $60.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 62/100 | $60M | 7 mo ago | Series B | 8 | Jacob Kimmel Co-Founder | SubstackSentryNode.js+13 | — | 4 job openings |
| 32 | Noctrix Health Developer of wearable therapeutic device to treat neurological disorders | $57M | 9 mo ago | Series C | 8 | — | WordPressApple iCloud MailMySQL+16 | — | — |
| 33 | ReviR Therapeutics Developer of RNA-based therapeutics for multiple diseases 35Funding top 26%AI top 45%Moat top 47%Talent bottom 49% All 8 signals ▾Fundingtop 26% AItop 45% Moattop 47% Talentbottom 49% Marketbottom 36% Globalbottom 36% Techbottom 31% Newsbottom 18% Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 1 mo ago | Series A | 29 | Yang Li Co-Founder | UbuntuElement UIVue.js+6 | — | 1 partnership |
| 34 | Spruce Developer of therapies for rare endocrine disorders | $50M | 8 mo ago | Public | 29 | Javier Szwarcberg CEO | WordPressMySQLPHP+25 | 5 patents Patents concentrated in electrical & electronics | — |
| 35 | Signos Provider of a wearable device for blood glucose pattern monitoring 42Tech top 20%Funding top 25%Moat top 39%Customers top 44% All 10 signals ▾Techtop 20% Fundingtop 25% Moattop 39% Customerstop 44% Producttop 46% Talentbottom 49% Marketbottom 40% Globalbottom 36% Growthbottom 31% Newsbottom 22% Tech: 52 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services Funding: Raised $37.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $37M | 0 mo ago | Series B | 30 | Sharam Fouladgar-Mercer Co-Founder & CEO | Webflow EcommerceWebflowGSAP+27 | — | — |
| 36 | Preventive Provider of genetic testing and research solutions for disease prevention and early detection | $30M | 7 mo ago | Seed | — | Lucas Harrington Founder & CEO | Cart FunctionalitySquarespace CommerceSquarespace+12 | 4 patents Dental prophylaxis formulations and wood preservation chemical technologies | — |
| 37 | Triomics Provider of clinical research and clinical trial tracking software 60AI top 20%Funding top 26%Talent top 38%Moat top 39% All 8 signals ▾AItop 20% Fundingtop 26% Talenttop 38% Moattop 39% Techtop 40% Growthtop 47% Globalbottom 43% Marketbottom 35% AI: Classified as an AI company Funding: Raised $28.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $29M | 0 mo ago | Series B | 29 | Hrituraj Singh Co-Founder & CTO | WixSentryEnvoy+20 | — | — |
| 38 | OncoSynergy Developer of resistance mechanism inhibitors to treat cancer 11Funding top 28%Moat top 32%Patents bottom 48%Global bottom 42% All 6 signals ▾Fundingtop 28% Moattop 32% Patentsbottom 48% Globalbottom 42% Innovationbottom 33% Marketbottom 18% Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $27M | 1 mo ago | Acquired | 3 | — | — | 26 patents Patents concentrated in chemistry & materials | — |
| 39 | Cofactor Genomics Developer of diagnostic assays using RNA sequencing 48Funding top 30%Moat top 32%Growth top 35%Tech top 39% All 11 signals ▾Fundingtop 30% Moattop 32% Growthtop 35% Techtop 39% AItop 45% Patentstop 46% Talentbottom 49% Innovationbottom 47% Globalbottom 40% Marketbottom 22% Newsbottom 18% Funding: Raised $26.2M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $26M | 6 mo ago | Series A | 9 | Jarret Glasscock Chief Executive Officer | WordPressApple iCloud MailGoogle Workspace+35 | 24 patents Patents concentrated in computing, sensing & instrumentation | — |
| 40 | SOLEY Therapeutics Developer of stem cell secreted factors for the treatment of myocardial infarction and stroke | $20M | 5 mo ago | Series C | 10 | Yerem Yeghiazarians Co-Founder & CEO | — | — | 1 job opening · 1 launch |
| 41 | Osteoboost Provider of a wearable medical device that utilizes targeted mechanical stimulation to deliver patented… 67Tech top 17%Talent top 28%Funding top 34%Growth top 35% All 6 signals ▾Techtop 17% Talenttop 28% Fundingtop 34% Growthtop 35% Globalbottom 48% Marketbottom 40% Tech: 49 technologies across 7/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 67/100 | $19M | 2 mo ago | Series A | — | Nikhil Viswanathan Founder | WordPressMySQLPHP+25 | — | — |
| 42 | General Proximity Developer of next generation of induced-proximity medicines 22Funding top 31%Talent bottom 49%Global bottom 48%Tech bottom 42% All 5 signals ▾Fundingtop 31% Talentbottom 49% Globalbottom 48% Techbottom 42% Marketbottom 24% Funding: Raised $16.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $16M | 1 mo ago | Seed | 11 | Armand Cognetta III Founder & CEO | WebflowVimeoGSAP+14 | — | — |
| 43 | Lighthouse Pharma Developer of therapeutics for neurology and infectious diseases 11Funding top 46%Talent bottom 49%Tech bottom 45%Global bottom 25% All 5 signals ▾Fundingtop 46% Talentbottom 49% Techbottom 45% Globalbottom 25% Marketbottom 18% Funding: Raised $15.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $15M | 1 mo ago | Series A | 4 | Casey Lynch Chief Executive Officer | WixSentryBootstrap+10 | — | 1 job opening |
| 44 | ParcelBio Developer of programmable technology to deliver mRNA to diverse cell types in the body | $13M | 4 mo ago | Seed | — | Christopher Carlson Co-Founder | — | — | — |
| 45 | Jaguar Health Developing gastrointestinal products for human prescription use and animals 50Product top 14%Funding top 24%Innovation top 34%Growth top 43% All 11 signals ▾Producttop 14% Fundingtop 24% Innovationtop 34% Growthtop 43% Talentbottom 49% Marketbottom 48% Fin. healthbottom 48% Moatbottom 45% Newsbottom 41% Techbottom 33% Globalbottom 32% Product: 4 distinct product lines · Company stage: Public Funding: Raised $11.6M across 28 rounds · 28 rounds over 12 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $12M | 5 mo ago | Public | 46 46 → 35 (-24%) · sector median +24% | Lisa Conte Founder & CEO | — | — | 1 launch · 1 partnership |
| 46 | Centivax Provider of drug discovery services 55Growth top 25%News top 28%Funding top 32%Patents top 32% All 9 signals ▾Growthtop 25% Newstop 28% Fundingtop 32% Patentstop 32% Innovationtop 40% Moattop 47% Globalbottom 40% Techbottom 39% Marketbottom 29% Growth: Fresh capital in last 24 mo News: 5 BI events in 12 mo (of 5 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $10M | 2 mo ago | Series A | 19 | — | Cart FunctionalitySquarespace CommerceSquarespace+12 | 39 patents Peptide-derived therapeutic antibodies and low-dose vaccine formulations targeting viral antigens | — |
| 47 | Valius Provider of molecular diagnostic testing services for identifying cancer vulnerabilities | $10M | 2 mo ago | Series A | — | Sarah Hesse Co-Founder & Head of Translational Science | — | — | — |
| 48 | Blank Bio Developer of RNA foundation models for precision medicine research applications 60Talent top 28%Funding top 35%Global bottom 48% All 3 signals ▾Talenttop 28% Fundingtop 35% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $7.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $7M | 1 mo ago | Seed | — | Jonathan Hsu Co-Founder & CEO | — | — | — |
| 49 | TippingPoint Biosciences Developer of therapeutics for treating diseases caused by dysfunctional genome chromatin packaging | $7M | 2 mo ago | Seed | — | Geeta Narlikar Co-Founder | WebflowGoogle Mapslit-html+13 | — | 1 partnership |
| 50 | 10x Science Provider of AI-native protein characterization platform for biopharma 37Talent top 28%AI top 35%Funding top 42%Tech bottom 46% All 6 signals ▾Talenttop 28% AItop 35% Fundingtop 42% Techbottom 46% Globalbottom 33% Marketbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-driven, ai-native rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 1 mo ago | Seed | — | Vishnu Tejus Co-Founder & CTO | Three.jsRadix UIElement UI+11 | — | — |
Top 12 Life Sciences companies in San Francisco
#1
Public · San Francisco, California · founded 2012 · 21 employees$420.1Mraised▾
Public · San Francisco, California · founded 2012 · 21 employees
Developer of therapeutics for orthopedic diseases. It offers a lead candidate NOV004 which is an anabolic peptide engineered to target and concentrate at the bone fracture site and also helps in spinal fusion and osteogenesis Imperfecta.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 13%Growth
top 37%Tech
top 44%Moat
top 48%Talent
bottom 49%Market
bottom 37%Funding: Raised $420M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Post IPO (May 2026)
Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Tech: 37 technologies across 3/8 capability areas · Cloud: Amazon Web Services, Cloudflare · Security: Cloudflare Bot Management, Hsts
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. LifeSci Capital) announced in 12 mo
Funding rounds
- May 2026Post IPO$187M
- Feb 2020Post IPO$125M
- May 2018Series B$84.5M
- Feb 2017Series A$7.6M
Founders & team
Investors
Breakout Labs, Dolby Family Ventures, Takeda, Pfizer Venture Investments, Takeda Ventures, Sequoia Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#2
Public · San Francisco, California · founded 2016 · 122 employees$158Mraised▾
Public · San Francisco, California · founded 2016 · 122 employees
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Funding
top 21%Talent
top 22%Tech
top 32%Innovation
top 34%News
bottom 43%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Post IPO (May 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- May 2026Post IPO$40M
- Dec 2024Post IPO$37.6M
- Dec 2024Post IPO$10M
- Jun 2024Grant (prize money)$8M
Founders & team
Investors
Matrix Partners China, Mirae Asset, Ridgeback Capital Management, Lux Capital, Gaingels, KB Investment
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAddthisAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#3
Series C · San Francisco, California · founded 2021 · 35 employees$250Mraised▾
Series C · San Francisco, California · founded 2021 · 35 employees
Developer of small-molecule therapeutics for cancer treatment. It provides a lysine-targeted covalency platform to develop therapies against known drug targets for oncology.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%Talent
top 28%Moat
top 31%Growth
top 35%Tech
top 49%Market
bottom 41%Funding: Raised $250M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series C (Apr 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Apr 2026Series C$108M
- Nov 2023Series B$175M
- May 2022Series A$75M
Founders & team
Investors
Orbimed, Third Rock Ventures, EcoR1, Novo Holdings, Cormorant Capital, RA Capital Management
Tech stack
All In One SeoAmazon Web ServicesApple Icloud MailBugherdCdnjsCloudflare
#4
Series D · San Francisco, California · founded 2019 · 154 employees$355Mraised▾
Series D · San Francisco, California · founded 2019 · 154 employees
Manufacturer of a medical device for cell-based therapy. The company offers Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. It also, offers software suite for cell therapy modalities.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Funding
top 15%News
top 19%Innovation
top 23%Growth
top 25%Patents
top 27%Moat
top 28%Funding: Raised $355M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jan 2026)
News: 9 BI events in 12 mo (of 25 tracked, 4 types) · +200% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Innovation: 89 patents (top 32% of patent-holders) · 83 filings since 2022 vs 6 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 31k LinkedIn followers — 5.1% of this cohort's audience · 94 engagements/post (3.5× cohort median)
Activity (LinkedIn): 1 partnerships · 1 awards · 1 expansions (incl. FDA) announced in 12 mo
Funding rounds
- Jan 2026Series D$257M
- Aug 2023Series C$255M
- Apr 2021Series B$82M
- Aug 2019Series A$18M
Founders & team
Investors
8VC, EcoR1, Eclipse, Decheng Capital, Skyviews Life Science, Koch Disruptive Technologies
Tech stack
Apple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCloudflare Browser InsightsCookieyes
#5
Public · San Francisco, California · founded 2019 · 34 employees$144.7Mraised▾
Public · San Francisco, California · founded 2019 · 34 employees
AI-driven drug discovery platform for neurological diseases based on patients biomarkers. The company's platform measures patients biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to develop personalized psychiatric drugs. The company has pipeline of drugs including ALTO-100 for depression, ALTO-101 for neurodegenerative diseases, and more.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 12%Patents
top 25%Growth
top 30%Moat
top 32%Innovation
top 33%Tech
top 45%Funding: Raised $145M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Post IPO (Mar 2026)
Patents: 57 patents matched (strict assignee match) · 57 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Growth: Headcount 12 → 34 (+183%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 25k LinkedIn followers — 4.0% of this cohort's audience · 64 engagements/post (2.3× cohort median)
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Mar 2026Post IPO$120M
- Oct 2025Post IPO$50M
- Nov 2023Series C$45M
- Jan 2023Venture Debt—
Founders & team
Investors
Lightswitch Capital, Novartis, Sobrato, Alkeon Capital Management, Windham Venture Partners, What If Ventures
Tech stack
Apple Icloud MailAstraBugherdCloudflareCore-JsElementor
#6
Series A · San Francisco, California · founded 2021 · 62 employees$108.5Mraised▾
Series A · San Francisco, California · founded 2021 · 62 employees
Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Patents
top 38%Talent
top 38%Market
top 46%Innovation
top 49%Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents · Soonicorn
Patents: 15 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Accounts Payable Clerk
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- Apr 2026Series A$5M
- Jun 2025Series A$25.4M
- Jul 2023Series A$48.5M
- Jun 2021Series A$60M
Founders & team
Investors
F-Prime Capital, Orbimed, Deerfield, Decheng Capital, RA Capital Management, LabCorp
#7
Seed · San Francisco, California · founded 2025$250Mraised▾
Seed · San Francisco, California · founded 2025
Developer of brain-computer interfaces to maximize human ability, agency, experience. It focuses on creating new approaches to interact with the brain. The aim is to develop high-bandwidth brain-computer interfaces. These interfaces integrate with advanced artificial intelligence. The goal is to make the technology safe and accessible. The company seeks to restore lost abilities and support healthier brain states. It also aims to deepen connections and expand creative potential.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Talent
top 28%Funding
top 31%AI
top 45%Patents
top 49%Innovation
bottom 49%Tech
bottom 45%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2026)
AI: Product described with: artificial intelligence
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Jan 2026Seed$250M
Founders & team
Investors
OpenAI
Tech stack
Apple Icloud MailGodaddyGoogle WorkspaceHstsNext.JsNext.Js App Router
#8
Public · San Francisco, California · founded 2011 · 19 employees$88.2Mraised▾
Public · San Francisco, California · founded 2011 · 19 employees
Developing targeted, immune-mediated oral cancer therapies for broad patient benefit. This clinical-stage biotechnology company focuses on creating small molecule therapeutics to treat cancer. Their approach involves mechanisms that directly target and kill tumor cells while simultaneously activating the body's own tumor-specific immunity. The company is developing first-in-class oral drug therapeutics with the potential to offer significant advantages to a wide range of cancer patients. They explore both new and validated pathways to discover and develop novel therapeutics. Their pipeline represents innovative approaches to cancer treatment, aiming to improve patient outcomes through targeted and immune-mediated strategies. The company's focus is on oncology drug discovery and development, with the goal of advancing novel therapeutics that will bring meaningful benefit to patients.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 28%News
top 36%Growth
top 42%Tech
top 49%Moat
bottom 43%Talent
bottom 41%Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) · Last round Post IPO (Mar 2026)
News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Web rank 5,000,000 → 10,000,000 YoY · 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
Funding rounds
- Mar 2026Post IPO$6M
- Mar 2026Post IPO$2M
- Feb 2020Series B$83.2M
- 2015Series A—
Founders & team
Investors
F-Prime Capital, Lilly Asia Ventures, Foresite Capital, Eight Roads Ventures, Versant Ventures, Quan Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#9
Series B · San Francisco, California · founded 2023$230Mraised▾
Series B · San Francisco, California · founded 2023
Developer of artificial intelligence models for de novo molecular design. The company focuses on engineering better molecules through advanced computational methods. It introduces new model series designed to achieve high hit rates in antibody design. The company provides access to its technology for molecular research and development.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 14%Talent
top 28%AI
top 30%Moat
top 32%Market
top 48%Global
bottom 48%Funding: Raised $230M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) · Last round Series B (Dec 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
AI: Classified as an AI company · Product described with: artificial intelligence
Audience (LinkedIn): 18k LinkedIn followers — 3.0% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. Pfizer) announced in 12 mo
Funding rounds
- Dec 2025Series B$130M
- Aug 2025Series A$70M
- Sep 2024Seed$30M
Founders & team
Investors
Thrive Capital, OpenAI, Menlo Ventures, Anthropic, Yosemite, DST Global
Tech stack
CloudflareFramer SitesGoogle AnalyticsGoogle Font ApiGoogle WorkspaceHsts
#10
Series B · San Francisco, California · founded 2020 · 30 employees$37Mraised▾
Series B · San Francisco, California · founded 2020 · 30 employees
Provider of a wearable device for blood glucose pattern monitoring. The company has developed an app-based platform that recommends meals and exercises for users based on the glucose pattern detected through the connected device. The app provides real-time glucose monitoring and glucose spike levels for different foods. Based on this, personalized fitness and nutrition plan can be developed.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Tech
top 20%Funding
top 25%Moat
top 39%Customers
top 44%Product
top 46%Talent
bottom 49%Tech: 52 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services · Devops: Envoy
Funding: Raised $37.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 9k LinkedIn followers
Funding rounds
- Oct 2023Series B$20M
- Nov 2021Series A$13M
- Jan 2021Seed$4M
Founders & team
Investors
Cheyenne Ventures, Google Ventures, Dexcom Ventures, Samsung NEXT, Courtside Ventures, 1984 Ventures
Tech stack
AddshoppersAmazon CloudfrontAmazon Web ServicesCloudflareCloudflare Bot ManagementCore-Js
#11
Series A · San Francisco, California · founded 2021 · 29 employees$54Mraised▾
Series A · San Francisco, California · founded 2021 · 29 employees
Developer of RNA-based therapeutics for multiple diseases. The company is leveraging machine learning technology and innovative RNA techniques to develop medicines for the treatment of cancer, rare genetic disorders, and infectious diseases.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%AI
top 45%Moat
top 47%Talent
bottom 49%Market
bottom 36%Global
bottom 36%Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series A (Apr 2026)
AI: Product described with: machine learning
Moat: Editorial + unicorn rating 3/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. CureCMT) announced in 12 mo
Funding rounds
- Apr 2026Series A—
- Nov 2025Grant (prize money)$4.6M
- Jul 2024Series A$30M
- Jan 2022Seed$20M
Founders & team
Investors
Lapam Capital, CDH, 5Y Capital, Yael Capital, Cmtrf, XtalPi
Tech stack
Core-JsElement UiGoogle WorkspaceLodashNginxSwiper
#12
Acquired · San Francisco, California · founded 2011 · 3 employees$26.7Mraised▾
Acquired · San Francisco, California · founded 2011 · 3 employees
Developer of resistance mechanism inhibitors to treat cancer. It targets multiple hallmarks of cancer progression and have demonstrated efficacy as monotherapy and in strategic combinations. The lead drug program OS2966 therapeutic antibody blocking a cell surface receptor for the treatment of glioblastoma, ovarian, pancreatic cancer, and malignant meningioma.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 28%Moat
top 32%Patents
bottom 48%Global
bottom 42%Innovation
bottom 33%Market
bottom 18%Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents
Patents: 26 patents matched (strict assignee match) · 4 filings since 2022 vs 12 in 2017-21 · Latest publication 2023
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- May 2022Series A$3.5M
- Nov 2020Conventional Debt$250K
- Sep 2020Series A$3.2M
- Jan 2020Grant (prize money)$300K
Investors
National Cancer Institute, Connecticut Innovations, Navation, KICC, HHS, JLABS
Funding & investor landscape
$36.8Btotal disclosed funding
585companies funded
1,845disclosed rounds
14rounds last 90 days
Most active investors
Notable founders
Dirk Thye
CEO · Quince Therapeutics
Jim Collins
Co-Founder · Senti Bio
Wilson Wong
Co-Founder · Senti Bio
Matt Jacobson
Co-Founder · Terremoto
Jack Taunton
Co-Founder · Terremoto
Fabian Gerlinghaus
Co-Founder & CEO · Cellares
Omar Kurdi
Co-Founder · Cellares
Amit Etkin
Founder & CEO · Alto Neuroscience
Manish Agarwal
Co-Founder · Adela
Scott Bratman
Co-Founder · Adela
Sumner Norman
Co-Founder · Merge Labs
Sandro Herbig
Co-Founder · Merge Labs
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research is surging — papers rose from 33 to 164, even as breakthroughs' overall field-share shrank from 41% to 30%.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements are intensifying — both jumped from ~3 to 62 papers, driving advancements' share from 29% to 35%.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern is rising sharply — papers tripled from 15 to 45 within biotechnology's US institutional research.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18350
- UNIV California18093
- Regeneron Pharma16106
- Amgen10600
- Monsanto Technology9821
- UNIV Pennsylvania8586
- Harvard College7497
- UNIV Texas7427
Common questions
How many Life Sciences companies are there in San Francisco, United States?
Radar tracks 892 indexable Life Sciences companies headquartered in San Francisco, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in San Francisco, United States?
The Life Sciences companies in San Francisco, United States on this list have raised a combined $36.8B in disclosed equity funding across 585 funded companies.
Which is the highest-funded Life Sciences company in San Francisco, United States?
Xaira is the highest-funded Life Sciences company in San Francisco, United States, with $1B in disclosed equity funding.
How many Life Sciences companies in San Francisco, United States are funded?
585 of the 892 Life Sciences companies in San Francisco, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in San Francisco, United States?
9 Life Sciences companies in San Francisco, United States on this list are valued at $1B or more.
Who are the top investors in San Francisco, United States Life Sciences companies?
The most active investors in San Francisco, United States Life Sciences companies on this list include HHS, Y Combinator, JLABS, SOSV, IndieBio.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.